Cidara Therapeutics’ long-acting antiviral biologic, CD-388, demonstrated robust efficacy in preventing seasonal influenza in healthy adults aged 18 to 64 in a randomized, placebo-controlled Phase 2b trial. The study showed statistically significant prevention efficacy across multiple dose groups, with protective effects lasting up to 28 weeks. CD-388 was well-tolerated with no unexpected dose-limiting adverse events. Cidara plans to initiate discussions with the FDA for Phase 3 trial design and envisages this biologic as a potential alternative to seasonal flu vaccines, addressing gaps in current prevention strategies and meeting a substantial medical need.